Brought to you by 
Conatus' $21.8mm FOPO to fund emricasan trials
29 Mar 2021
Executive Summary
Conatus Pharmaceuticals Inc. (hepatic diseases) netted $21.8mm in a follow-on public offering of 4mm shares (including the overallotment) at $5.75. It will use the money to continue developing and prep for registration trials of its Phase II pan-caspase protease inhibitor emricasan in post-liver transplant HCV clearance and liver cirrhosis (including with portal hypertension).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Conatus' $21.8mm FOPO to fund emricasan trials
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice